Pathophysiology of Sickle Cell Disease and New Drugs for the Treatment
2009

Pathophysiology of Sickle Cell Disease and New Drugs for Treatment

publication

Author Information

Author(s): Lucia De Franceschi

Primary Institution: University of Verona, Italy

Hypothesis

The study explores the biochemical properties of sickle hemoglobin and potential therapeutic strategies for sickle cell disease.

Conclusion

New pharmacological targets for treating sickle cell disease include agents that prevent dehydration of sickle cells and reduce their adhesion to endothelial cells.

Supporting Evidence

  • Hydroxycarbamide is the only drug currently approved for chronic use in sickle cell disease.
  • Long-term use of hydroxycarbamide has shown significant reductions in mortality and morbidity.
  • New therapeutic strategies include agents that prevent sickle cell dehydration and reduce sickle cell-endothelial adhesion.

Takeaway

Sickle cell disease happens because of a problem with hemoglobin, and scientists are looking for new ways to treat it by stopping sickle cells from getting dehydrated and sticking to blood vessels.

Digital Object Identifier (DOI)

10.4084/MJHID.2009.024

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication